K Ebina1, J Hashimoto, K Shi, M Kashii, M Hirao, H Yoshikawa. 1. Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan, k-ebina@umin.ac.jp.
Abstract
UNLABELLED: Patients with rheumatoid arthritis showed greater response to 18-month administration of daily teriparatide especially in the increase of bone formation markers at 1 month and femoral neck bone mineral density at 18 months compared to postmenopausal osteoporosis patients. INTRODUCTION: The aim of this study was to evaluate the effects of 18-month administration of daily teriparatide (TPTD) in osteoporosis patients with rheumatoid arthritis (RA) by comparing that of postmenopausal osteoporosis patients (Porosis). METHODS: The effects of TPTD were examined between RA (n = 70; age 68.4 years; disease activity score assessing 28 joints with CRP [DAS28-CRP] 2.8; rheumatoid factor [RF] positivity 75.5 %) with 77.1 % of prior bisphosphonate (BP), 84.3 % of oral prednisolone (PSL) (4.4 mg/day at baseline), 25.7 % of biologics, and Porosis (n = 62; age 71.3 years) with 77.4 % of prior BP. RESULTS: Femoral neck (FN) bone mineral density (BMD) increase at 18 months was significantly greater in RA compared to Porosis (4.7 vs. 0.7 %, P = 0.038), whereas it was 9.7 versus 7.9 % (P = 0.736) in the lumbar spine (LS). The increase of bone formation markers (bone alkaline phosphatase [bone ALP] and N-terminal type I procollagen propeptide [PINP]) at 1 month were all significantly greater in RA compared to Porosis. A multivariate logistic regression analysis revealed that the significant indicator of 18-month BMD increase in RA was a 3-month increase of under-carboxylated osteocalcin (ucOC) for LS (β = 0.446, P = 0.005) and baseline ucOC for FN (β = 0.554, P = 0.001), in which both showed significant negative correlation with baseline PSL dose. CONCLUSIONS: RA showed greater response to daily TPTD administration, especially in the increase of bone formation markers at 1 month and FN BMD increase at 18 months compared to Porosis.
UNLABELLED: Patients with rheumatoid arthritis showed greater response to 18-month administration of daily teriparatide especially in the increase of bone formation markers at 1 month and femoral neck bone mineral density at 18 months compared to postmenopausal osteoporosispatients. INTRODUCTION: The aim of this study was to evaluate the effects of 18-month administration of daily teriparatide (TPTD) in osteoporosispatients with rheumatoid arthritis (RA) by comparing that of postmenopausal osteoporosispatients (Porosis). METHODS: The effects of TPTD were examined between RA (n = 70; age 68.4 years; disease activity score assessing 28 joints with CRP [DAS28-CRP] 2.8; rheumatoid factor [RF] positivity 75.5 %) with 77.1 % of prior bisphosphonate (BP), 84.3 % of oral prednisolone (PSL) (4.4 mg/day at baseline), 25.7 % of biologics, and Porosis (n = 62; age 71.3 years) with 77.4 % of prior BP. RESULTS:Femoral neck (FN) bone mineral density (BMD) increase at 18 months was significantly greater in RA compared to Porosis (4.7 vs. 0.7 %, P = 0.038), whereas it was 9.7 versus 7.9 % (P = 0.736) in the lumbar spine (LS). The increase of bone formation markers (bone alkaline phosphatase [bone ALP] and N-terminal type I procollagen propeptide [PINP]) at 1 month were all significantly greater in RA compared to Porosis. A multivariate logistic regression analysis revealed that the significant indicator of 18-month BMD increase in RA was a 3-month increase of under-carboxylated osteocalcin (ucOC) for LS (β = 0.446, P = 0.005) and baseline ucOC for FN (β = 0.554, P = 0.001), in which both showed significant negative correlation with baseline PSL dose. CONCLUSIONS:RA showed greater response to daily TPTD administration, especially in the increase of bone formation markers at 1 month and FN BMD increase at 18 months compared to Porosis.
Authors: Peiqi Chen; Julie H Satterwhite; Angelo A Licata; E Michael Lewiecki; Adrien A Sipos; Derek M Misurski; Rachel B Wagman Journal: J Bone Miner Res Date: 2005-01-18 Impact factor: 6.741
Authors: S Mokuda; Y Okuda; M Onishi; N Sawada; K Matoba; A Yamada; K Jouyama; K Takasugi Journal: J Endocrinol Invest Date: 2011-09-30 Impact factor: 4.256
Authors: Yumie Rhee; Eun-Young Lee; Virginia Lezcano; Ana C Ronda; Keith W Condon; Matthew R Allen; Lilian I Plotkin; Teresita Bellido Journal: J Biol Chem Date: 2013-08-20 Impact factor: 5.157
Authors: Felicia Cosman; Robert A Wermers; Christopher Recknor; Karen F Mauck; Li Xie; Emmett V Glass; John H Krege Journal: J Clin Endocrinol Metab Date: 2009-07-07 Impact factor: 5.958
Authors: K Ebina; M Hirao; J Hashimoto; H Matsuoka; T Iwahashi; R Chijimatsu; Y Etani; G Okamura; A Miyama; H Yoshikawa Journal: Osteoporos Int Date: 2018-03-24 Impact factor: 4.507